Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 5/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.39 |
| ▸ | TNF | P01375 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 4/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | ACSS2 | Q9NR19 | 3/20 | 0.34 |
| ▸ | ASAH1 | Q13510 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9049120 | 0.89 | MAPT (0.38) | CYP11B1CYP11B2TNFHTTSMN1; SMN2 | |
| SCHEMBL2967845 | 0.86 | ACSS2 (0.38) | CYP11B1CYP11B2TNFHTTSMN1; SMN2 | |
| SCHEMBL3856673 | 0.81 | FGFR1 (0.45) | CYP11B1CYP11B2HTTSMN1; SMN2MAPK1 | |
| SCHEMBL29795166 | 0.79 | HTT (0.35) | CYP11B1CYP11B2TNFHTTSMN1; SMN2 | |
| SCHEMBL3037362 | 0.78 | NPC1 (0.39) | CYP11B1CYP11B2HTTSMN1; SMN2MAPK1 | |
| SCHEMBL1876428 | 0.78 | FGFR1 (0.45) | CYP11B1CYP11B2HTTMAPK1 | |
| SCHEMBL29447536 | 0.78 | NPC1 (0.39) | CYP11B1CYP11B2HTTSMN1; SMN2MAPK1 | |
| SCHEMBL2794301 | 0.76 | HTT (0.48) | CYP11B1CYP11B2TNFHTTSMN1; SMN2 | |
| SCHEMBL2968392 | 0.74 | NPC1 (0.39) | HTTSMN1; SMN2LMNA | |
| SCHEMBL6489900 | 0.74 | FGFR1 (0.45) | HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842688-B2 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2010-11-30 | — | — | US | disclosed |
| US-7790715-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-09-07 | — | — | US | disclosed |
| US-20090012055-A1 | Organic compounds | HEROLD PETER | 2009-01-08 | — | — | US | disclosed |
| EP-1961752-A2 | Piperidine Compounds | Speedel Experimenta AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| US-20070010511-A1 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2007-01-11 | — | — | US | disclosed |
| EP-1670760-A1 | ORGANIC COMPOUNDS | Speedel Experimenta AG (CH) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005061457-A1 | ORGANIC COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2005-07-07 | — | — | WO | disclosed |
| EP-0747355-A1 | NOVEL CARBAMATE DERIVATIVE AND MEDICINAL COMPOSITION CONTAINING THE SAME | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1996-12-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012055-A1 | Organic compounds | REN, ACE, ACE2 | CYP11B1 42/4885CYP11B2 18/4885TNF 4803/4885 |
| US-20070010511-A1 | Organic compounds | REN, ACE, ACE2 | CYP11B1 42/4885CYP11B2 18/4885TNF 4803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.